Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A randomized study of 6 vs 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse.
Jean‐Yves Blay, Camille Schiffler, Olivier Bouché, et al.
Annals of Oncology (2024)
Open Access | Times Cited: 12

Showing 12 citing articles:

Gastrointestinal Stromal Tumors
Gal Strauss, Suzanne George
Current Oncology Reports (2025)
Closed Access | Times Cited: 1
Next questions on gastrointestinal stromal tumors: unresolved challenges and future directions
D. Romandini, Paweł Sobczuk, Carlo María Cicala, et al.
Current Opinion in Oncology (2025)
Closed Access
Adjuvant treatment of gastrointestinal stromal tumor: State of the art in 2025
Nicolas Penel, Axel Le Cesne, Jean‐Yves Blay
European Journal of Cancer (2025), pp. 115473-115473
Closed Access
Duration of adjuvant imatinib treatment in GIST at high risk of relapse
Erman Akkuş
Annals of Oncology (2024) Vol. 35, Iss. 12, pp. 1205-1206
Closed Access | Times Cited: 2
Reply to the manuscript “A randomized study of 6 vs 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse” by J.-Y. Blay et al.
F. Petrelli, Lorenzo Dottorini, Antonio Ghidini
Annals of Oncology (2024)
Closed Access | Times Cited: 1
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update
Chunxiao He, Zilong Wang, Jiaying Yu, et al.
Current Treatment Options in Oncology (2024) Vol. 25, Iss. 11, pp. 1390-1405
Open Access | Times Cited: 1
Treatment of tenosynovial giant tumors with colony‐stimulating factor 1 receptor kinase inhibitors: When to start? When to stop? When to restart?
Jean‐Yves Blay, Armelle Dufresne, F. Gouin, et al.
Cancer (2024)
Closed Access | Times Cited: 1
Letter to the Editor regarding” randomized study of 6 vs 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse” by JY Blay at al.
Qiang Hu, Xiyin Yang, Qiang Hu, et al.
Annals of Oncology (2024)
Closed Access
Long-term adjuvant therapy for high-risk GIST: towards tailored imatinib duration?
Toshirou Nishida, Robin L. Jones
Annals of Oncology (2024)
Closed Access
Six years duration of adjuvant imatinib improves disease free survival in GIST with a high risk of relapse
Jean‐Yves Blay, Nicolas Penel, C Schiffler, et al.
Annals of Oncology (2024)
Closed Access
Six years duration of adjuvant imatinib in high risk GIST: more to come
Jean‐Yves Blay, C Schiffler, Sylvie Chabaud, et al.
Annals of Oncology (2024)
Closed Access
Author’s reply to the Letters to the Editor. Six years duration of adjuvant imatinib in high-risk GIST: more to come
Jean‐Yves Blay, C Schiffler, Sylvie Chabaud, et al.
Annals of Oncology (2024) Vol. 35, Iss. 12, pp. 1207-1208
Closed Access
Actualités 2024 par le Comité dé rédaction du Bulletin du Cancer : congrès ASCO, ESMO et au-delà
Stéphane Vignot, Audrey Bellesœur, Carole Bouleuc, et al.
Bulletin du Cancer (2024) Vol. 112, Iss. 1, pp. 19-34
Open Access
Page 1

Scroll to top